유니셀랩
1 known investors
Korean life-science R&D company developing pharmaceuticals and selling active pharmaceutical ingredients from Seongnam, Gyeonggi.
Also known as Unicellab · 유니셀랩(주)
Investors · 1
Company profile
researched Aug 2026유니셀랩(주) (Unicellab) is a South Korean company classified under physical, chemical and biological research and development. Its stated main businesses are life-science research and development, sale and wholesale/retail distribution of active pharmaceutical ingredients (원료의약품), and pharmaceutical research and development.
The company was established on 2018-09-21 and is registered as a small-and-medium enterprise (중소기업). It is headed by representative director 안지훈. Its facilities are located at 302 Galmachi-ro, Jungwon-gu, Seongnam-si, Gyeonggi-do (Seongnam Woolim Lions Valley 5th building), with unit 503-A serving as headquarters and 503-B as its research laboratory.
Business model
The company generates revenue from life-science and pharmaceutical research and development services together with the sale and wholesale/retail distribution of active pharmaceutical ingredients.
Traction
Revenue reached KRW 1.335 billion in fiscal 2024, up about 26% year over year, with operating profit of KRW 73.6 million and net profit of KRW 24.5 million. Total assets stood at KRW 2.803 billion against total liabilities of KRW 2.111 billion at end-2024, implying an equity ratio of 24.7% and a debt-to-equity ratio of 304.8%.
▸Full profile — market position, geography, history
Market position
Ranked 158th among peers in the Korean standard industrial classification for physical, chemical and biological R&D based on disclosed revenue.
Geography
Single site in Seongnam-si, Gyeonggi-do, South Korea, comprising a head office and an adjoining research laboratory.
History
Founded on 2018-09-21, the company reported growing annual revenue from KRW 368.75 million in 2021 to KRW 652.75 million in 2022, KRW 1.063 billion in 2023 and KRW 1.335 billion in 2024. Operating results moved from an operating loss of KRW 1.109 billion in 2021 and KRW 69.6 million in 2022 to operating profits of KRW 217.7 million in 2023 and KRW 73.6 million in 2024. Paid-in capital increased from KRW 58.8 million as of end-2022 and end-2023 to KRW 529.5 million as of 2024-12-31.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filings유니셀랩(주) was incorporated as a Korean small-and-medium enterprise in the physical, chemical and biological R&D sector.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- 유니셀랩 2024년 기업정보 - 직원수, 근무환경, 복리후생 등 | 잡코리아jobkorea.co.kr · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does 유니셀랩 do?
- Korean life-science R&D company developing pharmaceuticals and selling active pharmaceutical ingredients from Seongnam, Gyeonggi.
- Who are 유니셀랩's investors?
- 유니셀랩's investors include Laguna Investment.